Co-Director, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital
Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School

9:50 am – 10:35 am
The Francis Crick Institute

Session 2 – Expanding the Diagnostic Spectrum: Tools, Technologies, and Tracers

The market for neurological diagnostics is growing rapidly and expected to reach $13.6 billion by 2019. Which technologies will drive this new system? When will they be deployed and what are key barriers? Will there be sufficient discrete financial incentives to achieve the necessary innovation?

Moderator: Bruce Rosen, MD, PhD

Director, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital

Roger Gunn, PhD

CSO, Imanova
Professor of Molecular Neuroimaging, Department of Medicine, Imperial College, London

Jacob Hooker, PhD

Phyllis and Jerome Lyle Rappaport MGH Research Scholar, Director of Radiochemistry, Athinoula A. Martinos Center, Massachusetts General Hospital
Associate Professor in Radiology, Harvard Medical School

Robert Krieg, PhD

VP of MR Product Definition & Innovation, Siemens

Eddie Martucci, PhD

CEO, Akili Interactive Labs

Henrik Zetterberg, MD, PhD

Professor of Neurochemistry, Head of Lab, UCL
Professor of Neurochemistry, Head of Department, University of Gothenburg

10:35 am – 10:55 am
The Francis Crick Institute

Break (20 minutes)

10:55 am – 11:20 am
The Francis Crick Institute

1:1 Fireside Chat with John Lechleiter, PhD

Moderator: Hilary Evans

CEO, Alzheimer’s Research UK

John Lechleiter, PhD

Chairman, Eli Lilly and Company

11:20 am – 11:45 am
The Francis Crick Institute

Patient Interview

Martin Samuels, MD

Chair, Department of Neurology, Brigham and Women’s Hospital
Miriam Sydney Joseph Professor of Neurology, Harvard Medical School

Brenda and Stephen Whittle, PhD

Dementia Patient & Caregiver, Dementia Advocates and Volunteer Partners with ARUK (Alzheimer’s Research UK)

11:45 am – 12:30 pm
The Francis Crick Institute

Session 3 – Neurodegeneration and Neuroinflammation: A Grand Unifying Theory for Drug Development?

How will new immunity-focused insights and technologies drive neurodegeneration and neuroinflammatory diagnostics and therapies?

Moderator: Rudolph Tanzi, PhD

Vice-Chair of Neurology, Director of Genetics and Aging Research Unit, Massachusetts General Hospital
Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School

Christian Haass, PhD

Institute Head, German Center for Neurodegenerative Disease

Michael Hayden, MD, PhD

President of Global R&D, CSO, Teva Pharmaceutical Industries

Michael Hutton, PhD

CSO, Neuroscience, Eli Lilly and Company

Roger Nitsch, MD

President, Neurimmune Holding AG

Hugh Perry, PhD

Professor of Experimental Neuropathology, University of Southampton

12:30 pm – 1:40 pm
Biogen Seminar Suite | The Francis Crick Institute

Lunch Breakout 1 – Women and Dementia

Women have unique brain health challenges as they are twice as likely as men to have dementia. Additionally, women often take on the responsibility of caring for a loved one with the disease. This breakout will explore the efforts in sex-based brain health research and current funding challenges.

Moderator: Phyllis Ferrell

VP, Global Alzheimer’s Disease Platform Team, Eli Lilly and Company

Hilary Evans

CEO, Alzheimer’s Research UK

Jill Lesser

President Women Against Alzheimer’s

Reisa Sperling, MD

Director, Center for Alzheimer’s Research and Treatment, Brigham and Women’s Hospital
Professor of Neurology, Harvard Medical School

12:30 pm – 1:40 pm
Auditorium A | The Francis Crick Institute

Lunch Breakout 2 – Evolving Dementia Care: Government Policy in Action

How are the national dementia care strategies evolving? How does dementia care impact therapeutic innovation? Are we monitoring the impact of care beyond quality of life measures?

Moderator: Tim Ferris, MD

Senior Vice President of Population HealthCare Management, Partners HealthCare
Associate Professor of Medicine and Pediatrics, Harvard Medical School

Geoff Huggins

Director of Health Social Care and Integration, Scottish Government

Marc Wortmann

Executive Director, Alzheimer’s Disease International

12:30 pm – 1:40 pm
Auditorium B | The Francis Crick Institute

Lunch Breakout 3 – Depression and Neuroinflammation

Depressed patients often have high levels of inflammatory biomarkers, supporting the idea that certain psychiatric disorders could be an inflammatory response. As over half of all people with depression do not respond to conventional therapies, this breakout will explore the emerging research in anti-inflammatory treatments for CNS.

Moderator: Philip Iredale, PhD

VP Head of Circuits, Neuro-Opportunities & Screening, Technologies, Pfizer

Declan Jones, PhD

VP, Neuroscience Lead, J&J London Innovation Centre, Johnson & Johnson

Kerry Ressler, MD, PhD

CSO, McLean Hospital
Professor in Psychiatry, Harvard Medical School

12:30 pm – 1:40 pm
The Francis Crick Institute

Lunch Breakout 4 – Networking in Open Area

1:40 pm – 2:25 pm
The Francis Crick Institute

Session 4 – The Promise and Current Role of Gene and Cell Therapy as Treatments of Neurological Disease

Which diseases will be first? What are the barriers? When will there be clinical deployment?

Moderator: Ole Isacson, MD, PhD

Principal Investigator Harvard Stem Cell Institute, McLean Hospital
Professor of Neurology and Neuroscience, Harvard Medical School

Timothy Cox, MD

Professor of Medicine Emeritus, Director of Research, Honorary Consultant Physician, University of Cambridge

Brad Hyman, MD, PhD

Director, Massachusetts Alzheimer’s Disease Research Center, Massachusetts General Hospital
John B. Penney Professor of Neurology, Harvard Medical School

Gillian Leng, MD

Deputy Chief Executive, National Institute for Health and Care Excellence

Steven Paul, MD

CEO, Voyager Therapeutics

2:25 pm – 3:10 pm
The Francis Crick Institute

Session 5 – Next-Generation Therapies and Diagnostics: Big Data and Digital Health

As new HIT-driven systems and products are identified, what will influence new therapies and diagnostics? Which technologies will scale the fastest? How large do cohorts have to be to provide meaningful insights? Are there examples of real world successes?

Moderator: Shawn Murphy, MD, PhD

Corporate Director of Research Information Systems and Computing, Partners HealthCare
Associate Professor of Neurology, Harvard Medical School

Jenny Barnett, PhD

CSO, Cambridge Cognition

John Gallacher, PhD

Director, MRC Dementias Platform UK

Husseini Manji, MD

Global Therapeutic Area Head, Neuroscience, Janssen R&D

Richard Rudick, MD

VP Development Sciences, Biogen

Howard Weiner, MD

Director, Multiple Sclerosis Program, Brigham and Women’s Hospital
Robert L. Kroc Professor of Neurology, Harvard Medical School

3:10 pm – 3:35 pm
The Francis Crick Institute

1:1 Fireside Chat with Michael Ehlers, MD, PhD

Michael Ehlers, MD, PhD

EVP, Head of R&D, Biogen

3:35 pm – 3:55 pm
The Francis Crick Institute

Break (20 minutes)

3:55 pm – 4:40 pm
The Francis Crick Institute

Session 6 – Implementing Novel Models in Alzheimer’s Trials: How Can We Transform the Cost-Benefit Equation for Trials?

With an expanding Alzheimer’s pipeline, design challenges continue to limit the flexibility of trial execution. Which emerging solutions (e.g. digital technologies, data sharing, patient recruitment, alternative endpoints) will transform cost, duration, or value generated from future Alzheimer’s trials?

Moderator: Reisa Sperling, MD

Director, Center for Alzheimer’s Research and Treatment, Brigham and Women’s Hospital
Professor of Neurology, Harvard Medical School

Iain Chessell, PhD

VP Neuroscience IMED MedImmune, AstraZeneca

Michael Krams, MD

Global Head of Quantitative Sciences, Janssen Pharmaceuticals

Craig Ritchie, MD, PhD

Professor of Psychiatry of Ageing University of Edinburgh

Nadeem Sarwar, MD, PhD

President, AiM Institute, Eisai

4:40 pm – 5:25 pm
The Francis Crick Institute

Session 7 – The Crisis We Want: Are Healthcare Systems Prepared for a Disease-Modifying Drug?

There are currently 17 Alzheimer’s drugs entering Phase III over the next five years. What will be the response from payors, clinicians, and patient groups when those drugs finally reach patients? How can we find, treat, and provide drug access to all the right patients?

Moderator: Merit Cudkowicz, MD